Literature DB >> 32875375

Main genetic differences in high-grade gliomas may present different MR imaging and MR spectroscopy correlates.

Ángela Bernabéu-Sanz1, María Fuentes-Baile2, Cristina Alenda3.   

Abstract

OBJECTIVE: To assess whether the main genetic differences observed in high-grade gliomas (HGG) will present different MR imaging and MR spectroscopy correlates that could be used to better characterize lesions in the clinical setting.
METHODS: Seventy-nine patients with histologically confirmed HGG were recruited. Immunohistochemistry analyses for isocitrate dehydrogenase gene 1 (IDH1), alpha thalassemia mental retardation X-linked gene (ATRX), Ki-67, and p53 protein expression were performed. Tumour radiological features were examined on MR images. Metabolic profile and infiltrative pattern were assessed with MR spectroscopy. MR features were analysed to identify imaging-molecular associations. The Kaplan-Meier method and the Cox regression model were used to identify survival prognostic factors.
RESULTS: In total, 17.7% of the lesions were IDH1-mutated, 8.9% presented ATRX-mutated, 70.9% presented p53 unexpressed, and 22.8% had Ki-67 > 5%. IDH1 wild-type tumours had higher levels of mobile lipids (p = 0.001). The tumour-infiltrative pattern was higher in HGG with unexpressed p53 (p = 0.009). Mutated ATRX tumours presented higher levels of glutamate and glutamine (Glx) (p = 0.001). An association was observed between Glx tumour levels (p = 0.038) and Ki-67 expression (p = 0.008) with the infiltrative pattern. Survival analyses identified IDH1 status, age, and tumour choline levels as independent predictors of prognostic significance.
CONCLUSIONS: Our results suggest that IDH1-wt tumours are more necrotic than IDH1-mut. And that the presence of an infiltrative pattern in HGG is associated with loss of p53 expression, Ki-67 index, and Glx levels. Finally, tumour choline levels could be used as a predictive factor in survival in addition to the IDH1 status to provide a more accurate prediction of survival in HGG patients. KEY POINTS: • IDH1-wt tumours present higher levels of mobile lipids than IDH1-mut. • Mutated ATRX tumours exhibit higher levels of glutamate and glutamine. • Loss of p53 expression, Ki-67 expression, and glutamate and glutamine levels may contribute to the presence of an infiltrative pattern in HGG.

Entities:  

Keywords:  Glioma; Isocitrate dehydrogenase; Magnetic resonance imaging; Magnetic resonance spectroscopy; Tumor suppressor protein p53

Mesh:

Substances:

Year:  2020        PMID: 32875375     DOI: 10.1007/s00330-020-07138-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  37 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

2.  Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Authors:  Manila Antonelli; Francesca Romana Buttarelli; Antonietta Arcella; Sumihito Nobusawa; Vittoria Donofrio; Hiroko Oghaki; Felice Giangaspero
Journal:  J Neurooncol       Date:  2010-02-21       Impact factor: 4.130

Review 3.  Glioma epigenetics: From subclassification to novel treatment options.

Authors:  Olga Gusyatiner; Monika E Hegi
Journal:  Semin Cancer Biol       Date:  2017-11-21       Impact factor: 15.707

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Correlation among pathology, genotype, and patient outcomes in glioblastoma.

Authors:  Taku Homma; Takao Fukushima; Salvatore Vaccarella; Yasuhiro Yonekawa; Pier Luigi Di Patre; Silvia Franceschi; Hiroko Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  2006-09       Impact factor: 3.685

Review 6.  Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Authors:  Clifford J Belden; Pablo A Valdes; Cong Ran; David A Pastel; Brent T Harris; Camilo E Fadul; Mark A Israel; Keith Paulsen; David W Roberts
Journal:  Radiographics       Date:  2011-10       Impact factor: 5.333

Review 7.  The definition of primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

8.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

9.  The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Authors:  T A Juratli; M Kirsch; K Geiger; B Klink; E Leipnitz; T Pinzer; S Soucek; E Schrock; E Schrok; G Schackert; D Krex
Journal:  J Neurooncol       Date:  2012-09-27       Impact factor: 4.506

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

View more
  2 in total

1.  Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study.

Authors:  Jun Zhang; Hong Peng; Yu-Lin Wang; Hua-Feng Xiao; Yuan-Yuan Cui; Xiang-Bing Bian; De-Kang Zhang; Lin Ma
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

2.  Uncovering a Distinct Gene Signature in Endothelial Cells Associated With Contrast Enhancement in Glioblastoma.

Authors:  Fan Yang; Yuan Xie; Jiefu Tang; Boxuan Liu; Yuancheng Luo; Qiyuan He; Lingxue Zhang; Lele Xin; Jianhao Wang; Sinan Wang; Shuqiang Zhang; Qingze Cao; Liang Wang; Liqun He; Lei Zhang
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.